WO1995028930A1 - Dosage forms and method for ameliorating male erectile dysfunction - Google Patents
Dosage forms and method for ameliorating male erectile dysfunction Download PDFInfo
- Publication number
- WO1995028930A1 WO1995028930A1 PCT/US1995/004897 US9504897W WO9528930A1 WO 1995028930 A1 WO1995028930 A1 WO 1995028930A1 US 9504897 W US9504897 W US 9504897W WO 9528930 A1 WO9528930 A1 WO 9528930A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- apomorphine
- patient
- accordance
- patients
- milligrams
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69514794T DE69514794T2 (en) | 1994-04-22 | 1995-04-21 | SUBLINGUAL DOSAGE FORMS CONTAINING APOMORPHIN FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION |
JP52777595A JP3310982B2 (en) | 1994-04-22 | 1995-04-21 | Dosage forms and methods for ameliorating erectile dysfunction in men |
CA002188385A CA2188385C (en) | 1994-04-22 | 1995-04-21 | Dosage forms and method for ameliorating male erectile dysfunction |
MX9604981A MX9604981A (en) | 1995-04-21 | 1995-04-21 | Dosage forms and method for ameliorating male erectile dysfunction. |
DK95916467T DK0758895T3 (en) | 1994-04-22 | 1995-04-21 | Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction |
EP95916467A EP0758895B1 (en) | 1994-04-22 | 1995-04-21 | Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction |
AU22958/95A AU703608B2 (en) | 1994-04-22 | 1995-04-21 | Dosage forms and method for ameliorating male erectile dysfunction |
DE2001199068 DE10199068I2 (en) | 1994-04-22 | 1995-04-21 | Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction. |
AT95916467T ATE189121T1 (en) | 1994-04-22 | 1995-04-21 | SUBLINGUAL DOSAGE FORMS CONTAINING APOMORPHINE FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION |
HK98115585A HK1014239A1 (en) | 1994-04-22 | 1998-12-24 | Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction |
GR20000400773T GR3033084T3 (en) | 1994-04-22 | 2000-03-28 | Dosage forms and method for ameliorating male erectile dysfunction |
LU90856C LU90856I2 (en) | 1994-04-22 | 2001-11-23 | Uprima - apomorphine hydrochloride and its pharmaceutically acceptable derivatives |
NL300072C NL300072I1 (en) | 1994-04-22 | 2001-11-27 | Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23125094A | 1994-04-22 | 1994-04-22 | |
US231,250 | 1994-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995028930A1 true WO1995028930A1 (en) | 1995-11-02 |
Family
ID=22868404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/004897 WO1995028930A1 (en) | 1994-04-22 | 1995-04-21 | Dosage forms and method for ameliorating male erectile dysfunction |
Country Status (16)
Country | Link |
---|---|
US (3) | US5770606A (en) |
EP (2) | EP0978282B1 (en) |
JP (1) | JP3310982B2 (en) |
KR (1) | KR100374924B1 (en) |
AT (2) | ATE312609T1 (en) |
AU (1) | AU703608B2 (en) |
CA (1) | CA2188385C (en) |
DE (3) | DE69534693T2 (en) |
DK (2) | DK0758895T3 (en) |
ES (2) | ES2256999T3 (en) |
GR (1) | GR3033084T3 (en) |
HK (2) | HK1014239A1 (en) |
LU (1) | LU90856I2 (en) |
NL (1) | NL300072I1 (en) |
PT (1) | PT758895E (en) |
WO (1) | WO1995028930A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0833619A1 (en) * | 1995-06-13 | 1998-04-08 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
EP0834308A1 (en) * | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
WO1998026763A1 (en) * | 1996-12-16 | 1998-06-25 | Lts Lohmann Therapie-Systeme Gmbh | Active substance carrier for releasing apomorphine into the buccal cavity |
WO1998031368A1 (en) * | 1997-01-17 | 1998-07-23 | R.P. Scherer Limited | Dosage forms and method for ameliorating male erectile dysfunction |
WO1999062502A2 (en) * | 1998-05-29 | 1999-12-09 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
EP0992240A1 (en) * | 1997-05-29 | 2000-04-12 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for erection failure |
EP1094799A1 (en) * | 1998-06-22 | 2001-05-02 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
EP1105129A1 (en) * | 1998-08-24 | 2001-06-13 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
JP2001524509A (en) * | 1997-12-02 | 2001-12-04 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | Composition for nasal administration |
JP2001526686A (en) * | 1997-05-19 | 2001-12-18 | ゾナジェン,インコーポレイテッド | Combination therapy to modulate human sexual response |
AU2003204720B2 (en) * | 1998-05-29 | 2006-06-29 | Tap Pharmaceutical Products Inc. | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US20020165122A1 (en) * | 1994-04-22 | 2002-11-07 | Heaton Jeremy P. W. | Method and compositions for the treatment or amelioration of female sexual dysfunction |
US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
US6395744B1 (en) | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
AU751565B2 (en) * | 1995-06-13 | 2002-08-22 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
US5888534A (en) * | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
GB9514473D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
US6043252A (en) * | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
KR20010021625A (en) | 1997-07-09 | 2001-03-15 | 추후보정 | Improved Methods and Compositions for Treating Male Erectile Dysfunction |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
US20020002175A1 (en) * | 2000-09-19 | 2002-01-03 | Charanjit Behl | Nasal delivery of apomorphine in combination with glycol derivatives |
US6436950B1 (en) | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
US6284763B1 (en) | 1998-08-26 | 2001-09-04 | Queen's University At Kingston | Methods for remodeling neuronal and cardiovascular pathways |
US20040063719A1 (en) * | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
US6291471B1 (en) * | 1998-12-17 | 2001-09-18 | Abb Holdings, Inc. | Use of apomorphine for the treatment of organic erectile dysfunction in males |
US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
AU3490300A (en) * | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US7577475B2 (en) * | 1999-04-16 | 2009-08-18 | Cardiocom | System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus |
US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
EA004101B1 (en) * | 1999-09-03 | 2003-12-25 | Эли Лилли Энд Компани | Using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
CZ20023637A3 (en) | 2000-04-07 | 2003-02-12 | Tap Pharmaceutical Products, Inc. | Apomorphine derivatives and methods of their use |
US7223406B2 (en) * | 2000-07-21 | 2007-05-29 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
EP1365794A2 (en) * | 2000-07-21 | 2003-12-03 | Lue, Tom | Prevention and treatment of sexual arousal disorders |
FR2813193B1 (en) * | 2000-08-25 | 2003-08-15 | Pelvipharm | MEDICINE FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS BY ACTION ON THE CENTRAL NERVOUS SYSTEM |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
MXPA03004288A (en) | 2000-11-15 | 2004-09-10 | Tap Pharmaceutical Prod Inc | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine. |
US20020103105A1 (en) * | 2000-11-22 | 2002-08-01 | Brioni Jorge D. | Use of selective dopamine D4 receptor agonists for treating sexual dysfunction |
EP1224933A1 (en) * | 2001-01-19 | 2002-07-24 | Sanofi-Synthelabo | New combination of active ingredients containing alfuzosine and apomorphine |
MXPA03007081A (en) * | 2001-02-08 | 2004-10-15 | Pharmacia Corp | Rapid-onset medicament for the treatment of sexual dysfunction. |
US20030187011A1 (en) * | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
CA2474190A1 (en) * | 2002-02-07 | 2003-08-14 | Pharmacia Corporation | Pharmaceutical dosage form for mucosal delivery |
CA2479372A1 (en) * | 2002-03-19 | 2003-10-02 | Michael Holick | Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof |
JP4668611B2 (en) * | 2002-05-31 | 2011-04-13 | タイタン ファーマシューティカルズ インコーポレイテッド | Implantable polymer device for sustained release of buprenorphine |
GB0221711D0 (en) * | 2002-09-19 | 2002-10-30 | Ardana Bioscience Ltd | Methods |
US20040138291A1 (en) * | 2002-10-10 | 2004-07-15 | Adams Michael A. | Treatment of sexual dysfunction |
GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
US7943632B2 (en) * | 2003-03-17 | 2011-05-17 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
CN1777426A (en) | 2003-03-31 | 2006-05-24 | 泰坦医药品公司 | Implantable polymeric device for sustained release of dopamine agonist |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
US20060178394A1 (en) * | 2003-04-14 | 2006-08-10 | Staniforth John N | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
CA2529649C (en) * | 2003-06-17 | 2012-01-31 | Janssen Pharmaceutica N.V. | Substituted spirobenzazepines |
AU2006299833B2 (en) | 2005-10-12 | 2012-04-12 | Besins Healthcare Luxembourg Sarl | Improved testosterone gel and method of use |
WO2007084591A2 (en) * | 2006-01-20 | 2007-07-26 | Janssen Pharmaceutica N.V. | Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
PT2442650E (en) | 2009-06-12 | 2015-12-18 | Cynapsus Therapeutics Inc | Sublingual apomorphine |
DK2651357T3 (en) | 2010-12-16 | 2020-06-02 | Sunovion Pharmaceuticals Inc | Sublingual film |
EP3524247A1 (en) * | 2013-11-11 | 2019-08-14 | Impax Laboratories, Inc. | Rapidly disintegrating formulations and methods of use |
AU2015274462A1 (en) * | 2014-06-12 | 2016-12-22 | University Of Notre Dame Du Lac | Composition and method for the treatment of neurological diseases and cerebral injury |
JP7211706B2 (en) | 2015-04-21 | 2023-01-24 | サノヴィオン ファーマシュティカルズ インコーポレーテッド | Method for treating Parkinson's disease by administering apomorphine to oral mucosa |
EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | Data compression and communication using machine learning |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2818855A (en) * | 1954-02-11 | 1958-01-07 | Anthony P Miller | Surgical device |
US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4543256A (en) * | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
US4687773A (en) * | 1983-03-28 | 1987-08-18 | Mclean Hospital | (+)-N-N-propylnorapomorphine and selective limbic activity |
US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
DE69434304T2 (en) * | 1993-03-26 | 2005-12-29 | Merkus, Franciscus Wilhelmus H.M. | Pharmaceutical compositions for the intranasal administration of dihydroergotamine |
-
1995
- 1995-04-21 WO PCT/US1995/004897 patent/WO1995028930A1/en active IP Right Grant
- 1995-04-21 DE DE69534693T patent/DE69534693T2/en not_active Expired - Fee Related
- 1995-04-21 AT AT99121684T patent/ATE312609T1/en not_active IP Right Cessation
- 1995-04-21 KR KR1019960705906A patent/KR100374924B1/en not_active IP Right Cessation
- 1995-04-21 JP JP52777595A patent/JP3310982B2/en not_active Expired - Fee Related
- 1995-04-21 EP EP99121684A patent/EP0978282B1/en not_active Expired - Lifetime
- 1995-04-21 DK DK95916467T patent/DK0758895T3/en active
- 1995-04-21 PT PT95916467T patent/PT758895E/en unknown
- 1995-04-21 EP EP95916467A patent/EP0758895B1/en not_active Expired - Lifetime
- 1995-04-21 DK DK99121684T patent/DK0978282T3/en active
- 1995-04-21 DE DE69514794T patent/DE69514794T2/en not_active Expired - Lifetime
- 1995-04-21 ES ES99121684T patent/ES2256999T3/en not_active Expired - Lifetime
- 1995-04-21 CA CA002188385A patent/CA2188385C/en not_active Expired - Fee Related
- 1995-04-21 ES ES95916467T patent/ES2143049T3/en not_active Expired - Lifetime
- 1995-04-21 AU AU22958/95A patent/AU703608B2/en not_active Ceased
- 1995-04-21 DE DE2001199068 patent/DE10199068I2/en active Active
- 1995-04-21 AT AT95916467T patent/ATE189121T1/en active
- 1995-10-20 US US08/546,498 patent/US5770606A/en not_active Expired - Fee Related
-
1998
- 1998-06-22 US US09/102,235 patent/US5985889A/en not_active Expired - Fee Related
- 1998-12-24 HK HK98115585A patent/HK1014239A1/en not_active IP Right Cessation
- 1998-12-24 HK HK00104970A patent/HK1025742A1/en not_active IP Right Cessation
-
1999
- 1999-11-15 US US09/440,451 patent/US6200983B1/en not_active Expired - Fee Related
-
2000
- 2000-03-28 GR GR20000400773T patent/GR3033084T3/en not_active IP Right Cessation
-
2001
- 2001-11-23 LU LU90856C patent/LU90856I2/en unknown
- 2001-11-27 NL NL300072C patent/NL300072I1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
Non-Patent Citations (3)
Title |
---|
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, Volume 26, issued 1988, P. DANJOU et al., "Assessment of Erectogenic Properties of Apomorphine and Yohimbine in Man", pages 733-739. * |
JOURNAL OF UROLOGY, Volume 145, issued June 1991, R. SEGRAVES et al., "Effect of Apomorphine on Penile Tumescence in Men with Psychogenic Impotence", page 1175. * |
PROGRESS OF NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, Volume 12, issued 1988, S. LAL, "Apomorphine in the Evaluation of Dopaminergic Function in Man", pages 117-164. * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0833619A4 (en) * | 1995-06-13 | 1998-12-30 | Pentech Pharmaceuticals Inc | Controlled release of drugs delivered by sublingual or buccal administration |
EP0833619A1 (en) * | 1995-06-13 | 1998-04-08 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
EP0834308A1 (en) * | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
US5814638A (en) * | 1996-09-30 | 1998-09-29 | Lg Chemical Ltd. | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
AU746373B2 (en) * | 1996-12-16 | 2002-04-18 | Lts Lohmann Therapie-Systeme Gmbh | Active substance carrier for releasing apomorphine into the buccal cavity |
WO1998026763A1 (en) * | 1996-12-16 | 1998-06-25 | Lts Lohmann Therapie-Systeme Gmbh | Active substance carrier for releasing apomorphine into the buccal cavity |
WO1998031368A1 (en) * | 1997-01-17 | 1998-07-23 | R.P. Scherer Limited | Dosage forms and method for ameliorating male erectile dysfunction |
AU717337B2 (en) * | 1997-01-17 | 2000-03-23 | R.P. Scherer Limited | Dosage forms and method for ameliorating male erectile dysfunction |
US6342246B2 (en) | 1997-01-17 | 2002-01-29 | R.P. Scherer Limited | Image forms and method for ameliorating male erectile dysfunction |
JP2009280621A (en) * | 1997-05-19 | 2009-12-03 | Repros Therapeutics Inc | Combination therapy for modulating human sexal response |
JP2001526686A (en) * | 1997-05-19 | 2001-12-18 | ゾナジェン,インコーポレイテッド | Combination therapy to modulate human sexual response |
EP0992240A4 (en) * | 1997-05-29 | 2003-04-16 | Mochida Pharm Co Ltd | Therapeutic agent for erection failure |
EP0992240A1 (en) * | 1997-05-29 | 2000-04-12 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for erection failure |
JP2001524509A (en) * | 1997-12-02 | 2001-12-04 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | Composition for nasal administration |
JP4754067B2 (en) * | 1997-12-02 | 2011-08-24 | アルキメデス ディヴェロプメント リミテッド | Composition for nasal administration |
US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
WO1999062502A3 (en) * | 1998-05-29 | 2000-06-15 | Univ Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
AU764009B2 (en) * | 1998-05-29 | 2003-08-07 | Tap Pharmaceutical Products Inc. | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
AU2003204720B2 (en) * | 1998-05-29 | 2006-06-29 | Tap Pharmaceutical Products Inc. | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
WO1999062502A2 (en) * | 1998-05-29 | 1999-12-09 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
EP1094799A1 (en) * | 1998-06-22 | 2001-05-02 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
EP1094799A4 (en) * | 1998-06-22 | 2002-05-08 | Pentech Pharmaceuticals Inc | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
EP1105129A1 (en) * | 1998-08-24 | 2001-06-13 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
EP1105129A4 (en) * | 1998-08-24 | 2003-11-12 | Pentech Pharmaceuticals Inc | Amelioration of apomorphine adverse effects |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0758895B1 (en) | Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction | |
US6306437B1 (en) | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction | |
AU752928B2 (en) | Treatment of female sexual dysfunction | |
AU710111B2 (en) | Methods and formulations for modulating the human sexual response | |
US6087362A (en) | Apomorphine and sildenafil composition | |
US6566368B2 (en) | Apomorphine-containing dosage form for ameliorating male erectile dysfunction | |
CZ20004653A3 (en) | Apomorphine and antiemetic intended for use in therapy, apomorphine mixture, antiemetics, and medicamentous form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2188385 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019960705906 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995916467 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995916467 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995916467 Country of ref document: EP |